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Inhibition of differentiation has been proposed as an important mechanism for Myc-induced tumorigenesis,
but the mechanisms involved are unclear. We have established a genetically defined differentiation model in
human leukemia K562 cells by conditional expression of the cyclin-dependent kinase (Cdk) inhibitor p27
(inducible by Zn2) and Myc (activatable by 4-hydroxy-tamoxifen). Induction of p27 resulted in erythroid
differentiation, accompanied by Cdk inhibition and G1 arrest. Interestingly, activation of Myc inhibited
p27-mediated erythroid differentiation without affecting p27-mediated proliferation arrest. Microarray-based
gene expression indicated that, in the presence of p27, Myc blocked the upregulation of several erythroid-cell-
specific genes, including NFE2, JUNB, and GATA1 (transcription factors with a pivotal role in erythropoiesis).
Moreover, Myc also blocked the upregulation of Mad1, a transcriptional antagonist of Myc that is able to
induce erythroid differentiation. Cotransfection experiments demonstrated that Myc-mediated inhibition of
differentiation is partly dependent on the repression of Mad1 and GATA1. In conclusion, this model demon-
strates that Myc-mediated inhibition of differentiation depends on the regulation of a specific gene program,
whereas it is independent of p27-mediated cell cycle arrest. Our results support the hypothesis that differen-
tiation inhibition is an important Myc tumorigenic mechanism that is independent of cell proliferation.
c-Myc (Myc herein after) is an oncogenic transcription fac-
tor of the helix-loop-helix/leucine zipper (HLH-LZ) protein
family that elicits a variety of biological responses related to
cell cycle control, genomic instability, immortalization, ener-
getic metabolism, ribosome biogenesis, apoptosis, intercellular
communication, and control of cell differentiation (for reviews,
see references 5, 17, 21, and 40). Myc forms heterodimers with
the protein Max and the Myc-Max dimers bind to E-boxes in
regulatory regions to transactivate genes. Also, an important
number of Myc target genes (30 to 50% across different stud-
ies) are repressed by Myc-Max in an E-box-independent man-
ner (18, 27, 39, 58; see also the Myc target gene database
[www.myccancergene.org]). The mechanism for Myc-mediated
transactivation involves chromatin acetylation, whereas the
mechanisms for Myc-mediated transrepression remain poorly
defined, with the exception of a few genes (1, 9, 11, 41). On the
other hand, Max form dimers with proteins of the Mad family.
Mad proteins are also HLH-LZ proteins that function as Myc
antagonists, since Mad-Max dimers repress transcription upon
binding to E-boxes (5, 21). Consistent with the Myc effects on
cultured cells and transgenic models, deregulated expression
of Myc is found in a wide array of human cancers, in many
cases associated with disease progression (30, 36).
Work in different mouse models has demonstrated that Myc
promotes differentiation in some tissues by expanding the stem
cell population (53, 56) or by promoting both proliferation and
differentiation of immature precursors (22). However, en-
forced Myc expression blocks differentiation of a wide variety
of cell types both in vitro and in vivo (for reviews, see refer-
ences 21 and 40). Actually, inhibition of differentiation was one
of the first biological effects described for Myc (8, 16, 44).
However, in contrast to the extensive research carried out on
the mechanisms by which Myc enhances proliferation, the
mechanisms for the Myc-mediated suppression of differentia-
tion are much less known. Since proliferation and differentia-
tion are usually mutually exclusive and Myc drives cells into
proliferation, it has been argued that Myc prevents terminal
differentiation by blocking the cell cycle exit (21, 40). Consis-
tently, Myc induces the expression of genes that promote cell
cycle progression (cyclins D2 and E1, Cdk4) and represses cell
cycle inhibitors as p21Waf1 and p27Kip1 (referred to as p27
hereafter) (30).
p27 was originally described as a negative regulator of cell-
cycle progression through the inhibition of cyclin-dependent
kinases (Cdks) (37, 46). However, p27 has also been involved
in biological functions unrelated to cell cycle, including the
differentiation of erythroid precursors (14, 48). Regarding he-
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matopoiesis, p27 is expressed in CD34 progenitor cells and in
the primitive erythroid precursors (48, 55), but p27-deficient
mice do not show gross abnormalities in the hematopoietic
lineages (reviewed in reference 34).
A functional antagonism between Myc and p27 in prolifer-
ation has been well established: Myc and p27 loss cooperates in
animal carcinogenesis models (31), and several reports dem-
onstrate the ability of Myc to abrogate p27 function (7, 43, 51,
54) and expression (54). However, in sharp contrast to the
information on the antagonism between Myc and p27 in pro-
liferation, the possible Myc-p27 cross talk in differentiation has
not been investigated.
The study of Myc effects on differentiation has been im-
paired by the complex array of pathways activated by cytokines
and chemicals used as differentiation inducers in most model
systems. We previously showed that induction of p27 results in
erythroid differentiation of K562 (35), and here we have investi-
gated the role of Myc in this genetically defined differentiation
model. We found that Myc blocks p27-mediated differentiation
but that it cannot rescue the p27-dependent proliferation arrest
and Cdk inhibition. We also report that Myc blocks the upregu-
lation of Mad1 and of a set of erythroid-differentiation-determin-
ing genes such as the transcription factor GATA1.
MATERIALS AND METHODS
Cell culture, differentiation assays, and transfections. K562 cells were grown
in RPMI 1640 medium supplemented with 8% fetal calf serum and antibiotics.
Kp27MER and KMER4 sublines were generated electroporating the pBABE-
MycER plasmid (28) into Kp27-5 and KMT sublines, which have been described
previously (35). The Kp27pBP and KMTpBP sublines were generated by elec-
troporating Kp27-5 and KMT with pBABE-puro vector. A total of 107 cells were
electroporated with 20 g of DNA (260 V and 1 mFa in a Bio-Rad gene pulser)
and selected with 1 g of puromycin (Sigma)/ml. Cells (2.5  105 cells/ml) were
treated with ZnSO4 to induce p27 expression, and 4-hydroxy-tamoxifen (4HT;
Sigma) to activate MycER. Unless otherwise stated, ZnSO4 and 4HT were used
at 75 M and 100 nM, respectively. Transient transfection of Kp27MER (80,000
cells) was carried out with Lipofectamine 2000 (Invitrogen) with 1.2 g of
pEF-GATA1 (50) and pEF-NFE2 (29) vectors or empty vector. Nucleofections
of K562 cells were performed in a Nucleofector (Amaxa) according to the
manufacturer’s indications with pCEFL-Myc (32), pCEFL-Mad1 (constructed by
inserting human Mad1cDNA into the pCEFL vector), pCEFL-p27 (35), pCEFL-
MycV394D, pME-MycD106-143 (49), CMV-MadMyc (6), pEF-GATA1, pEF-
NFE2, and 0.25 g of a green fluorescent protein (GFP) vector (pmaxGFP;
Amaxa) to assess transfection efficiency.
Proliferation and cell cycle assays. Cell counting was performed in hemacy-
tometer. For DNA synthesis assay, cells were pulsed with 30 M bromodeoxyuri-
dine (BrdU; Roche Applied Science) for 1 h, fixed in 90% ethanol, treated with
RNase and HCl, and incubated with fluorescein isothiocyanate-conjugated anti-
BrdU monoclonal antibody (Roche Applied Science) for 30 min as described
previously (34). Cells were analyzed by flow cytometry (Excalibur; BD Bio-
sciences). For cell cycle analysis, cells were resuspended in phosphate-buffered
saline (PBS)-sodium citrate buffer containing 10 g of bovine serum albumin/ml,
200 g of RNase/ml, and 50 g of propidium iodide (Sigma Chemical Co.)/ml.
The cells were incubated at 37°C in darkness for 30 min and then analyzed by
flow cytometry using CellQuest software.
RNA analysis. Total RNA was isolated by using an RNeasy kit (Qiagen). For
reverse transcription-PCR (RT-PCR), first-strand cDNA was synthesized from 1
g of total RNA by using SuperScript II RNase reverse transcriptase (Invitro-
gen) with random primers. Quantitative PCR (qPCR) was performed with a
QuantiTect Sybr green PCR kit (Qiagen). The sequences of the primers used and
amplicon sizes are shown in the Table S1 in the supplemental material. The data
were normalized to ribosomal protein S14 (RPS14) mRNA levels. RPS14 has not
been described as the Myc target gene (www.myccancergene.org).
Luciferase reporter assays. Three million of Kp27MER cells were electropo-
rated at 260 V and 1 mFa in a Bio-Rad electroporator with 3 g of pGL2-M4-
Luc reporter (24) and 1 g of pRL-TK (Promega). After 24 h of incubation,
cultures were split into aliquots and further incubated for 24 h with ZnSO4
and/or 4HT. Cells were lysed, and the luciferase activity was measured in dupli-
cate by a dual-luciferase reporter gene assay system (Promega). The data were
normalized against the Renilla luciferase activity.
Gene expression profiling. Biotinylated cRNA was obtained from total RNA
and hybridized to Affymetrix HG-U133A chip in the Genomic Facility of Centro
de Investigacio´n del Cancer (Salamanca, Spain). The data analysis and hierar-
chical tree clusters were generated by using the dChip software (26; see also
http://biosun1.harvard.edu/complab/dchip/). The expression data was filtered so
as to include genes with expression changes 2.3-fold and with a signal differ-
ence 50 between compared samples. The analysis was performed with data
from two independent experiments and RNA preparations of each treatment
(control, ZnSO4, 4HT, and ZnSO4  4HT) in Kp27MER and K562. The inter-
action network for differentially expressed genes was generated by using Inge-
nuity Pathways Analysis software.
Immunofluorescence and immunoblotting. For immunofluorescence, Kp27MER
cells were treated with ZnSO4 and/or 4HT for 12 and 24 h and immunostained
with the anti-Myc and anti-p27 antibodies, as well as with DAPI (4,6-di-
amidino-2-phenylindole) to stain nuclei. A total of 2  104 to 5  104 Kp27MER
cells were centrifuged at 1,500 rpm for 5 min, resuspended in 8 l of PBS, and
dried on microslides. Cells were fixed for 15 min in 3.7% paraformaldehyde in
PBS at room temperature and permeabilized with 0.5% Triton X-100 for 30 min.
The cells were then incubated with primary (16 h at 4°C), washed, and incubated
with secondary antibodies (1 h at room temperature). The primary antibodies
used were anti-Myc rabbit polyclonal antibody and anti-p27 mouse monoclonal
antibody (both diluted 1:25). Secondary antibodies were conjugated with Texas
Red or FITC (Jackson Laboratories). Cells were mounted with antifading
mounting medium Vectashield (Vector Laboratories) with DAPI to visualize the
nuclei. Images were recorded by using a Bio-Rad MRC 1024 confocal laser
microscope. Immunoblots were performed as previously described (35). Blots
were revealed with an ECL system (Amersham). The antibodies used are de-
scribed in Table S2 in the supplemental material.
Immunoprecipitations and kinase activity assays. Protein extracts (500 g per
assay) were immunoprecipitated with 1 g of anti-cyclin D2, cyclin D3, and Cdk2
and p27 antibodies (see Table S2 in the supplemental material). Immunopre-
cipitation and kinase activity assays were performed as described previously (35).
Microarray data were deposited in the ArrayExpress database under accession
number E-MEXP-1772.
RESULTS
Generation of K562 sublines with conditional expression of
p27 and Myc. We previously reported that induction of p27 in
K562 human myeloid cells resulted in G1 arrest and erythroid
differentiation (35). We took advantage of this differentiation
system to ask whether Myc interferes with p27-mediated dif-
ferentiation and to study the possible mechanisms involved.
For this purpose, we first generated cells with conditional ex-
pression of both p27 and Myc. Kp27-5 cells (which carry a
Zn2-inducible p27 allele) were stably transfected with an ex-
pression vector for the fusion protein MycER, where Myc
activity is activated by 4HT (28). One of the transfectants,
termed Kp27MER, was selected, and immunoblot analysis
confirmed that the cells expressed MycER and retained p27
induction by Zn2. The activation of MycER by 4HT was
assessed, first, by the Myc downregulation of endogenous Myc
(Fig. 1A), an effect observed in many cell lines, including K562
(12, 42). We further confirmed the activation of MycER by
transactivation assays with a luciferase reporter carrying E-
boxes (Fig. 1B). Immunofluorescence studies demonstrated
that, in Kp27MER cells, ZnSO4 induced a dramatic accumu-
lation of p27 in cell nucleus and that the concomitant activa-
tion of Myc by 4HT did not modify this p27 localization (Fig.
1C). Altogether, the results demonstrated the activation of
MycER in response to 4HT in Kp27MER cells.
Myc inhibits p27-induced erythroid differentiation. We next
sought to determine whether Myc could antagonize the ery-
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throid differentiation mediated by p27. Kp27MER cells were
treated with ZnSO4 to induce p27 and 4HT to activate Myc,
and the erythroid differentiation was analyzed first by the frac-
tion of cells containing hemoglobin as determined by the ben-
zidine test. This fraction was reduced by 4HT in Kp27MER
cells but not in control Kp27pBP cells (Fig. 2A). Myc effect was
further confirmed by the expression of erythroid-cell-specific
genes as glycophorin A (GYPA), erythropoietin receptor
(EPOR), -globin, and ε-globin. mRNA levels of these genes
were induced by p27, and this induction was blocked by 4HT
(Fig. 2B). Finally, Myc also reversed the morphological differ-
entiation into erythroid phenotype induced by p27, as shown by
the dramatic reduction in the number of basophilic erythro-
blast-like cells (Fig. 2C). Altogether, the results show that Myc
inhibited p27-induced differentiation.
Myc does not antagonize the proliferation arrest mediated
by p27. As proposed for other models, we explored the possi-
bility that Myc could inhibit erythroid differentiation by main-
taining the cells in a proliferative state. When p27 was induced
with 75 M Zn2, Kp27MER cells underwent a rapid growth
arrest, similar to that induced by p27 in control cells
(Kp27pBP) (Fig. 3A). In agreement with the growth determi-
nations, p27 induction was accompanied by S-phase depletion
and G1-phase arrest (Fig. 3B). Surprisingly, the activation of
Myc by 4HT in these conditions did not reverse this arrest (Fig.
3A), and cell cycle analysis revealed the G1-phase arrest pro-
voked by p27 upon treatment with 75 M Zn2 was not mod-
ified by Myc (i.e., by 4HT treatment) (Fig. 3B). Treatment with
lower Zn2concentrations (50 M) resulted in moderate p27
levels (Fig. 3C) and a less severe proliferation arrest than with
higher p27 levels (i.e., with 75 M Zn2) (Fig. 3A). Consis-
tently, moderate p27 levels (i.e., with 50 M Zn2) induced a
weaker differentiation, which was also blunted by Myc (not
shown). In the presence of moderate p27 levels, however, Myc
provoked a slight but consistent increase in proliferation (Fig.
3A). This effect depended on Myc since 4HT did not modify
the proliferation rate of control Kp27pBP cells (Fig. 3A). Con-
sistently, Myc provoked an increase in the fraction of cells in S
phase when the cell cycle was analyzed (Fig. 3B). In agreement
with this result, Myc reversed the moderate repression of the
mitotic cyclin B1 in cells treated with 50 M Zn2, as deter-
mined by immunoblot analysis (Fig. 3D). In contrast, the ex-
FIG. 1. Myc activation and p27 induction in Kp27MER cells.
(A) Kp27MER cells were incubated with 100 nM 4HT and/or 75 M
ZnSO4 during 24 h, and protein extracts were analyzed by Western
blotting with antibodies to Myc, p27, and -tubulin as a loading con-
trol. (B) Induction of Myc transactivation activity in Kp27MER in
response to 4HT. Cells were electroporated with a Myc-responsive
luciferase construct, and after 24 h the cultures were split into aliquots
and further incubated for 24 h with ZnSO4 and/or 4HT as indicated.
The data represent promoter activity normalized against the Renilla
luciferase activity. (C) Double immunofluorescence showing p27 and
Myc subcellular localization. Kp27MER cells were treated for 12 and
24 h with ZnSO4 and/or 4HT as indicated. Cytospin preparations were
subjected to immunofluorescence with anti-Myc and anti-p27 antibod-
ies and stained with DAPI to visualize the nuclei.
FIG. 2. Myc inhibits the erythroid differentiation induced by p27.
(A) Cells were treated for 72 h with ZnSO4 and 4HT, and the fraction
of hemoglobinized cells was assayed by the benzidine test. Values are
means  the standard deviations (SD) of three experiments.
(B) Downregulation of erythroid genes by Myc. Kp27MER as well as
control Kp27pBP cells were treated with ZnSO4 and 4HT as indicated.
The expression of the GYPA, EPOR, -globin, and ε-globin expression
was determined by RT-qPCR. Cells were incubated with ZnSO4
and/or 4HT for 24 h except GYPA (72 h). Expression levels were
graphed relative to untreated Kp27MER cells. The data are means 
the standard errors of the mean (SEM) of three independent experi-
ments. (C) Kp27MER cells were treated for 96 h with 75 M ZnSO4
and 200 nM 4HT as indicated, and cytospin preparations were stained
by the May-Gru¨nwald-Giemsa method. Micrographs of representative
fields are shown. Arrows indicate cells with morphological features of
erythroid differentiation resembling basophilic erythroblasts.
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pression of the erythroid gene -globin was similarly blunted
by Myc in the presence of 75 or 50 M Zn2. The results were
confirmed by measurements of DNA synthesis by BrdU incor-
poration assays. As expected, DNA synthesis was halted in
Kp27MER cells treated with 75 M Zn2 (i.e., high p27 lev-
els). Activation of Myc did not relieve this inhibition (Fig. 3E).
However, DNA synthesis was not totally inhibited in cells
treated with 50 M Zn2 (moderate p27 levels), and Myc
induced a moderate increase in DNA synthesis (Fig. 3E). We
conclude that Myc inhibits p27-induced erythroid differentia-
tion without reversing the p27-mediated cell cycle arrest.
Myc does not reverse p27-mediated inhibition of Cdks. The
best-defined biochemical activity of p27 is the inhibition of Cdk
activity. Thus, we sought to determine whether Myc impaired
this activity in the K562 model in conditions where Myc is
blocking differentiation. We first compared the expression of
cyclins D and Cdk4, Cdk6, and Cdk2 in cells arrested and
differentiated by p27 (i.e., treated with ZnSO4) and in cells
with the differentiation blocked after Myc activation (i.e.,
treated with ZnSO4 and 4HT) (Fig. 4A). p27 induced the
accumulation of cyclins D, an effect likely due to protein sta-
bilization since there was no upregulation of cyclins D mRNA
(data not shown). Myc also induced a small increase in cyclin
A, cyclin D2, Cdk4, and Cdk2. No significant changes were
observed in parental K562 cells treated with ZnSO4 or 4HT
(results not shown).
In most models, the G1-phase arrest by p27 is associated
with retinoblastoma (RB) hypophosphorylation. Immunoblot
experiments show that this was also the case in Kp27MER
treated with ZnSO4. Interestingly, in the presence of p27, most
of the RB remained hypophosphorylated upon 4HT addition
(Fig. 4B). We next analyzed the levels of RB phosphorylated in
Ser780 and Thr821 using phospho-specific antibodies. Phos-
phorylation in Ser780 and Thr821 have been reported as spe-
cific for Cdk4/6 and Cdk2, respectively (25, 57). Immunoblot
results confirmed that p27 profoundly repressed RB phos-
phorylation and that Myc could reverse none of them.
We next studied the kinase activity in cyclin D2 and cyclin
D3 complexes, the most prevalent cyclin D forms in K562 (Fig.
4A and data not shown) using RB protein as substrate. In this
setting, the kinase activity assayed is mostly due to Cdk2, Cdk4,
and Cdk6. The kinase activity was dramatically inhibited by
p27, and Myc only slightly reversed this inhibition (Fig. 4C),
which is consistent with the small increase in phospho-RB
observed in 4HT-treated cells (Fig. 4B). K562 cells are defi-
cient in p15INK4B and p16INK4A (13), and thus these proteins
cannot contribute to Cdk4/6 inhibition in this system. Since RB
is also the substrate for Cdk2 kinase activity, we assayed the
kinase activity after immunoprecipitation with anti-Cdk2 anti-
body and in the presence or absence of Myc (i.e., with or
without 4HT treatment). The results showed a dramatic inhi-
bition of Cdk2 activity in p27-expressing cells, which was un-
changed by Myc (Fig. 4C). Thus, Myc cannot reverse the in-
hibition of Cdk4/6 and Cdk2 elicited by p27. The possibility still
FIG. 3. Myc induced proliferation in p27-arrested cells is p27 dose dependent. (A) Growth curves of Kp27MER and Kp27pBP cells treated with
(E) or without (F) 4HT and 75 or 50 M ZnSO4. Values are means  the SD of three experiments. (B) Cell cycle analysis of Kp27MER treated
for 24 h with 100 nM 4HT and 50 or 75 M ZnSO4 as indicated. The percentages of the cells in each cell cycle phase are indicated.
(C) Dose-dependent expression of p27. Kp27MER cells were treated with 50 and 75 M ZnSO4 and 4HT for 24 h, and the expression of p27 and
-tubulin (as loading control) was assayed by immunoblotting. (D) Kp27MER cells were treated with the indicated concentrations of ZnSO4 and
4HT, and the expression of cyclin B1 (to assay proliferation), -globin (to assay differentiation), and actin (as loading control) was assayed by
immunoblotting. (E) DNA synthesis in Kp27MER cells assayed by BrdU incorporation. Cells were incubated during 24 h with or without 4HT and
75 or 50 M ZnSO4 and pulsed for 1 h with BrdU, and the incorporation of the nucleoside was determined by flow cytometry. The graph shows
the percentages of BrdU-positive cells. The data are means  the SD from three independent experiments.
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existed that Cdk inhibition was a secondary effect of the p27-
induced differentiation rather than the inhibitory interaction of
p27 with cyclin-Cdk complexes. Thus, we studied the proteins
associated with p27 by immunoprecipitation experiments.
Cdk2, Cdk4, and Cdk6 were found in p27 immunoprecipitates,
and Myc did not modify their levels (Fig. 4D). However, Myc
activation also resulted in greater amounts of cyclins D. Thus,
we also tested the possibility that Myc modified the affinity of
p27 for cyclin D-Cdk4/6 complexes. However, Myc activation
did not change the relative amounts of p27, Cdk4, and Cdk6
present in cyclin D2 and D3 immunoprecipitates (Fig. 4E) and
correlated to the amounts present in total extracts (Fig. 4A and
data not shown). The results are again consistent with the lack
of recovery in Cdk activity (Fig. 4C). Taken together, the data
demonstrate that Myc inhibited p27-induced erythroid differ-
entiation without reversing the p27-dependent inhibition of
Cdks, a result that is consistent with the inability of Myc to
reverse p27-mediated proliferation arrest.
Myc antagonizes the upregulation of erythroid-cell-specific
genes mediated by p27. Since Myc inhibited Kp27MER differ-
entiation without rescuing the cells from the G1 arrest imposed
by p27, this model provided an ideal opportunity to identify
proliferation-independent targets of Myc that may explain its
activity as a differentiation inhibitor. We therefore carried out
microarray analysis with the Affymetrix platform testing RNA
from Kp27MER cells either untreated or treated for 12 h with
ZnSO4, 4HT, or both. The experimental conditions and asso-
ciated phenotypes, as well as the number of regulated genes,
are schematized in Fig. 5A. We focused in the genes regulated
by Myc in the presence of p27, comparing the transcriptomes
of Kp27MER treated with ZnSO4 with cells treated with
ZnSO4 plus 4HT. After subtracting the genes changed in con-
trol samples, filtering, and statistical analysis, we found that
Myc regulated 200 genes with 2.3-fold change, being 121
genes downregulated (see Table S3 in the supplemental mate-
rial). The clustering analysis of these genes showed that all
Myc-expressing cells cluster together (Fig. 5B). This data set
was further analyzed with the Ingenuity Pathways software to
reveal the network of interactions between differentially regu-
lated genes in the Kp27MER cells after induction of Myc and
thus assaying the possible relevance of Myc activation in this
model. The results revealed that the top-ranked network had
Myc at the most significant node of interactions among pro-
teins whose expression levels (at the mRNA level) changed
between cells treated with ZnSO4 and cells treated with ZnSO4
plus 4HT (Fig. 5C). This result argues that Myc is responsible
for the phenotypic change of Kp27MER cells upon addition
of 4HT.
Myc downregulates erythroid genes. Microarray analysis re-
vealed that a significant fraction of the genes downregulated by
Myc in the presence of p27 were erythroid cell related (see
Table S4 in the supplemental material), and the same result
was observed for other erythroid genes (e.g., ε-globin and
-globin). Interestingly, some of these genes downregulated by
Myc encode transcription factors able to drive erythroid dif-
ferentiation in cell culture, as well as in in vivo models, such as
GATA1, NFE2, STAT5A, STAT3, LMO2, LYL1, and JUNB.
Moreover, Myc upregulated genes that block erythroid differ-
entiation, such as the NOTCH ligand JAG2 and the transcrip-
tion factor MAFK. Myc-mediated regulation of GATA1,
NFE2, JUNB, and MAFK mRNA levels was confirmed by
RT-qPCR (Fig. 6A). In contrast, Myc did not antagonize the
p27-mediated downregulation of genes involved in DNA rep-
lication and mitosis, in agreement with the inability of Myc to
FIG. 4. Myc does not reverse Cdk inhibition by p27. (A) Expression
of G1-phase cyclins and Cdks. Protein extracts of Kp27MER cells
treated for 24 h with or without 4HT and ZnSO4 were assayed by
immunoblotting for the indicated cyclins and Cdks. (B) Myc does not
reverse RB hypohosphorylation. Total RB levels and phospho-specific
RB levels were determined by immunoblotting in Kp27MER cells. See
Table S2 in the supplemental material for antibody details. The posi-
tion of hypophosphorylated RB and hyperphosphorylated RB (pRB)
are marked by arrowheads. (C) Cdk activity determination. Lysates
were immunoprecipitated with antibodies to cyclin D2, cyclin D3, and
Cdk2 and assayed for kinase activity using RB (for cyclins) or histone
H1 (For Cdk2) as a substrate. The kinase activity was normalized
against the amounts of cyclin D2, D3, and Cdk2 pulled down in the
immunoprecipitates. (D) Composition of p27 complexes. Lysates from
Kp27MER cells treated with ZnSO4 and/or 4HT were immunoprecipi-
tated with anti-p27 antibodies, and the levels of p27, cyclin D1, D2, D3,
Cdk6, Cdk4, and Cdk2 in the immunoprecipitates were assayed by im-
munoblotting. The corresponding nonimmunoprecipitated samples are
shown in panel A. (E) Cyclin D2 and D3 immunoprecipitations. Cells
were treated with ZnSO4 and/or 4HT, lysates were immunoprecipitated
with cyclin D2 or cyclin D3 antibodies, and the levels of p27, Cdk4, and
Cdk6 in the immunoprecipitates were assayed by immunoblotting.
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reverse p27-mediated growth arrest as cyclins E, Cdk1, Cdc6,
Cdc25A, PCNA, RFCs, and MCMs (results not shown). We
sought to confirm the effect of Myc on p27-induced differen-
tiation observed in the Kp27MER cell line in the parental
K562 cells. For this, K562 cells were transiently transfected
by nucleofection with expression vectors for p27 and Myc.
In agreement with the results obtained with the Kp27MER
line, p27-transfected K562 cells overexpressed erythroid-cell-
specific genes such as GYPA and EPOR, and transfection of
Myc vector inhibited this effect (Fig. 6B). It has been described
that Myc represses genes through the interaction with the zinc
finger protein Miz1, forming a complex that binds to the region
of the transcription initiation site (reviewed in reference 52).
To test the possibility that Miz1 could be involved in the
repression of erythroid genes and to confirm the effects of Myc
on p27-induced differentiation, we transiently transfected K562
cells with expression vectors for p27, Myc, and MycV394D, a
mutant unable to bind Miz1 (23). MycV394D was as efficient as
wild-type Myc in antagonizing the upregulation of GATA1 and
NFE2 induced by p27 (Fig. 6B). Consistently, we did not detect
binding of Myc to the region of GATA1 gene that contains the
transcription initiation site by chromatin immunoprecipitation
(data not shown). This result suggests that Myc repress
GATA1 and NFE2 through a Miz1-independent mechanism.
We also sought to determine whether the Myc effect is depen-
dent on Myc box II. This region is required for transactivation,
for transformation, and also for gene repression activities of
Myc (reviewed in references 21 and 40). The results showed
that MycD106-143 (carrying a deletion that encompasses Myc
box II) was much less efficient at antagonizing p27-mediated
upregulation of GATA1 and NFE2 (Fig. 6B) and other ery-
throid markers as ε-globin and EPOR (data not shown).
GATA1 antagonizes the effect of Myc as an inhibitor of
erythroid differentiation. Of the genes regulated by Myc, we
focused on GATA1 and NFE2, two transcription factors es-
sential for erythroid lineage commitment (19). In erythroid
differentiation, GATA1 nucleates the subsequent binding (2).
Thus, we sought to determine whether GATA1 and NFE2
were partly responsible for the p27-induced differentiation by
transiently transfecting Kp27MER cells. We first confirmed by
immunoblot analysis that GATA1 transfection and overexpres-
sion did not modify the induction of p27 by ZnSO4 (Fig. 6C).
Activation of Myc (i.e., by 4HT treatment) impaired erythroid
differentiation, as assessed by the diminished upregulation of
GYPA (Fig. 6D), ε-globin (Fig. 6E), and the fraction of he-
moglobinized cells (data not shown). However, differentiation
was increased to some extent by GATA1 coexpression (Fig.
6D,E). We also transfected Kp27MER cells with NFE2 expres-
sion vector (Fig. 6F). In contrast to GATA1, NFE2, at the
levels achieved in the transfections, did not rescue the differ-
entiation inhibitory effect of Myc as assayed by ε-globin ex-
pression (Fig. 6G) and benzidine staining (not shown). When
both GATA1 and NFE2 were cotransfected, the effect was
similar to that achieved by GATA1 alone (data not shown).
Thus, downregulation of GATA1 is involved in the differenti-
ation inhibition by Myc, but other additional mechanisms seem
to be operative.
Myc antagonizes Mad1 upregulation mediated by p27. It has
been shown that Mad1, which forms dimers with Max that
repress transcription, antagonizes Myc functions. In addition,
FIG. 5. Myc-regulated genes in the Kp27MER system. (A) Scheme
of the Kp27MER samples subjected to microarray analysis and the
resulting phenotypes. Cells were treated for 12 h with ZnSO4 and
4HT. The numbers of genes regulated (2.3-fold) are indicated in
red. Gene expression changes between samples separated by the red
line are subjected to clustering analysis in panel B. (B) Heat map of
clustered samples and genes of expression data of duplicated sam-
ples of Kp27MER treated with ZnSO4 (i.e., p27) in the presence or
absence of 4HT (i.e., Myc). The hierarchical clustering was per-
formed for genes with expression variation 2.3-fold between cells
expressing p27 and cells expressing p27 and Myc (P 	 0.005), after
subtraction of the corresponding controls in parental K562 cells.
The genes are listed in the Table S3 in the supplemental material.
The scale at the bottom shows the relationship between color sat-
uration and the expression ratios. (C) Interaction network for dif-
ferentially expressed genes in the presence of Myc and p27. A
knowledge-based database (Ingenuity Pathways Analysis) was
seeded with the differentially expressed genes between cells ex-
pressing p27 and cells expressing p27Myc shown in panel B.
Genes in red were upregulated and those in gray were downregu-
lated in the samples treated with 4HT (i.e., Myc). The figure rep-
resents the network with the highest score identified by the program
and shows Myc (in blue) at a central node of the network. The
meanings of node shape and lines are indicated at the bottom.
VOL. 28, 2008 Myc INHIBITS p27-INDUCED DIFFERENTIATION 7291
it has been reported that Mad1 induces erythroid differentia-
tion in Friend murine erythroleukemia cells (10). Thus, we
sought to determine whether the functional antagonism be-
tween Myc and Mad1 could also contribute to explain the
Myc-mediated inhibition of differentiation in the K562 system.
We assayed the expression of Mad proteins in the Kp27MER
system and found that Mad1 protein (Fig. 7A) and mRNA
(Fig. 7B) was upregulated upon p27-induced differentiation.
Interestingly, Mad1 upregulation was reduced when Myc was
activated by 4HT (Fig. 7A and B). In contrast, other members
of the Mad family such as Mnt and Mxi1 were not upregulated
by p27 (Fig. 7A). Moreover, transient transfection of p27 in
K562 resulted in an increase in Mad1 mRNA (not shown). We
next sought to determine whether Mad1 could contribute to
p27-induced differentiation in this model. Cells were tran-
siently transfected with expression vectors for Mad1 and Myc,
and the erythroid differentiation was assayed by the benzidine
test and the expression of ε-globin and EPOR. The results
showed that Mad1 increased the expression of differentiation
markers (Fig. 7D and E). We also transfected the MadMyc
construct, which carries the transrepression domain of Mad1
linked to the HLH-LZ domain of Myc and acts as a strong
repressor of Myc-responsive transcription (6). MadMyc was
transfected into K562, and its expression demonstrated by im-
munoblotting (Fig. 7C). We found that MadMyc efficiently
induced differentiation as assessed by the upregulation of
EPOR and ε-globin genes (Fig. 7E). Finally, coexpression of
Myc blunted the differentiation induced by Mad1 and by Mad-
Myc in transient-transfection experiments (Fig. 7C and D). We
conclude that Mad1 upregulation is part of the differentiation
response and that Myc also functions as a Mad1 antagonist in
this system.
DISCUSSION
One of the first biological activities described for Myc was
differentiation inhibition, namely, the chemically induced ery-
throid differentiation of FMEL cells (8, 16, 44). This effect is
consistent with the erythroleukemia induced in transgenic mice
with enforced Myc expression in erythroid precursors (47).
However, the mechanisms by which Myc blocks differentiation
are poorly understood. Proliferation stimulation can certainly
contribute to Myc-mediated inhibition of differentiation, but
the hypothesis that Myc exerts proliferation-independent
mechanisms to block differentiation has received little atten-
tion. Several studies have shown that Myc antagonizes the cell
cycle arrest effect of p27, and the prevalent mechanism pro-
posed is the sequestration of p27 in type D cyclins complexes
(7, 43, 51). In contrast, there is little information on whether
and how Myc impairs p27-induced differentiation. In this con-
text, it has been shown that the monocytic differentiation in-
duced by retinoic acid in U937 myeloid cells is mediated by p27
and inhibited by Myc (15) and that inactivation of p27 gene
rescues the cerebellar development otherwise impaired in N-
Myc-deficient mice (59).
We have established a genetically defined model system
where differentiation can be induced in K562 human myeloid
leukemia cells by p27 induction and Myc can be conditionally
activated. The molecular mechanisms by which p27 induces
differentiation in this model are unknown. However, they do
FIG. 6. Erythroid genes downregulated by Myc. (A) Kp27MER
and K562 cells were incubated for 12 h with ZnSO4 and/or 4HT, and
mRNA levels of the indicated erythroid transcription factor genes
were determined by RT-qPCR. Values represent means  the SEM of
three independent experiments. (B) Expression of erythroid genes in
K562 cells after transient transfection of vectors for p27, Myc, Myc-
V394D (MycVD), and Myc D106-143 (MycD106). The plasmids were
nucleofected, and the mRNA levels of GYPA, EPOR (24 h after
transfection), or GATA1 and NFE2 (48 h after transfection) were
determined by RT-qPCR. An expression vector for GFP was cotrans-
fected in each case, and the data were normalized to the expression of
GFP. Values are means  the SEM from four independent experi-
ments. (C) Enforced expression of GATA1 in Kp27MER. Cells were
transfected by lipofection with GATA1 or empty vector. At 12 h after
transfection, cells were treated with ZnSO4 and/or 4HT. After 24 h of
incubation, the expression of GATA1, p27, and Myc was analyzed by
immunoblotting. The anti-GATA1 antibody used recognizes the N-
terminal domain of mouse protein. (D) GYPA mRNA levels assayed
by RT-qPCR in Kp27MER cells transiently transfected with GATA1.
At 12 h after transfection the cells were treated for 72 h with ZnSO4
and 4HT, and the mRNA level was determined by RT-qPCR. Values
are means  the SEM of two independent experiments. (E) ε-Globin
mRNA levels of Kp27MER transfected with GATA1, assayed as in
panel D. (F) Enforced expression of NFE2 in Kp27MER. Cells were
transfected with an NFE2 expression vector or empty vector and an-
alyzed by immunoblotting as in panel C. (G) ε-Globin mRNA levels of
Kp27MER transfected with NFE2, assayed as in panel D. The data are
means  the SEM of two independent experiments.
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not entirely depend on cell cycle arrest since p21 also arrests
proliferation of K562 while inducing a different type of differ-
entiation (34). In the present study we show that Myc impairs
the erythroid differentiation through a mechanism that is in-
dependent of the proliferation arrest and Cdk inhibition im-
posed by p27. Thus, the Myc effect on differentiation inhibition
is uncoupled from its effects on proliferation. Microarray anal-
ysis showed that Myc antagonizes the p27-mediated upregula-
tion of genes of transcription factors that direct erythroid dif-
ferentiation (GATA1, NFE2, JUNB, LMO2, and STAT5A).
Myc also antagonizes the p27-mediated downregulation of
genes that oppose erythroid differentiation (MAFK and
JAG2). Moreover, enforced expression of GATA1, a “master
gene” of erythropoiesis (19), partially rescues the differentia-
tion inhibition induced by Myc, indicating that Myc effect is
mediated, in part, by antagonizing GATA1 induction. How-
ever, GATA1 is only partly rescuing the anti-differentiation
effect of Myc, since Myc is likely impairing differentiation by
repressing several erythroid-determining genes.
The molecular mechanism by which Myc represses GATA1
is unclear. Actually, about half of Myc target genes are re-
pressed, but the mechanism of repression is unknown for the
vast majority of the genes. In a small subset of genes, Myc-
mediated repression depends on the interaction with Miz1
(52). In the case of GATA1 in the K562 model, this effect
seems to be Miz1 independent, since a Myc mutant unable to
bind Miz1 antagonized the upregulation of GATA1 and ery-
throid differentiation as efficiently as did wild-type Myc. In
contrast, a Myc mutant lacking Myc box II (a conserved region
required for transformation, transactivation, and repression
activities of Myc) cannot efficiently antagonize p27-induced
differentiation in our model. This result has also been observed
for other differentiation models (4, 20) and suggests that Myc
is using a common molecular mechanism to transform and to
abrogate differentiation. On the other hand, it has been re-
ported that GATA1 represses Myc and induces p27 in murine
embryonic cells (45), suggesting the possibility of a regulatory
p27-GATA1 loop. However, GATA1 does not repress Myc in
our K562 model (data not shown).
Myc and Mad1 have antagonist activities in transcription
upon binding to the same E-boxes and in cell proliferation (5,
21). We found that p27-induced differentiation of K562 is
accompanied by Mad1 upregulation and that Mad1 is able to
promote K562 erythroid differentiation, although less effi-
ciently than p27. Moreover, MadMyc, a chimeric protein that
represses gene expression upon binding to Myc-binding sites
(6), is a potent differentiation inducer. Thus, Myc would an-
tagonize this Mad1 effect at the transcriptional level. Further-
more, Myc activation in our model provokes Mad1 downregu-
lation in K562 cells and Myc coexpression impairs Mad1 and
MadMyc-induced differentiation. This suggests that the im-
pairment of Mad1 function by Myc is contributing to differen-
tiation inhibition in the K562p27MER model. These results
are consistent with Mad1 inducing erythroid differentiation of
murine erythroleukemia cells (10). Moreover, it has been
shown that Mad1 and p27 cooperate for a correct development
of the myeloid compartment in vivo (33). Similar scenery
seems to operate in K562 differentiation, and our data suggest
that Myc might impair the Mad1-p27 functional interaction.
In summary, the results in the K562 model demonstrate that
the differentiation-inhibitory effect of Myc depends on its gene
regulatory activity and is uncoupled from its effect as prolifer-
ation stimulator. Importantly, tumor cell redifferentiation is
the mechanism for the tumor regression after Myc deactivation
in some transgenic mice models (reviewed in reference 3).
FIG. 7. Mad1 induction by p27 and repression by Myc. (A) Immu-
noblot showing Mad1 expression in Kp27MER cells treated with 200
nM 4HT and the indicated concentrations of ZnSO4. The expression
of p27, Mnt, and Mxi1 (members of the Mad family) was also deter-
mined. The levels of p21 and endogenous Myc are also shown to
confirm the activation of Myc by 4HT. (B) Expression of Mad1 mRNA
in Kp27MER and K562 cells. Cells were treated for 12 h with 4HT and
ZnSO4, and mRNA expression was determined by RT-qPCR. The
data are means  the SEM of three experiments. (C) Mad1 induces
the expression of erythroid markers in K562, and Myc impairs the
Mad1-induced differentiation. K562 cells were nucleofected with ex-
pression vectors for Mad1, Myc, the MadMyc hybrid construct, and a
mixture of Mad1Myc and MadMycMyc vectors. At 24 h after
transfection, the expression of the ectopic proteins was analyzed by
immunoblotting. (D) K562 cells were transfected as in panel C, and the
benzidine-positive cells were scored 72 h after transfection to assess
erythroid differentiation. The data are means  the SEM of two
independent experiments. (E) EPOR and ε-globin mRNA levels were
assayed by RT-qPCR in K562 cells transiently transfected as described
in panel C. The data are means  the SEM of two independent
experiments.
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Moreover, Myc is one of the four transcription factor set ca-
pable of conferring pluripotent stem cell properties to differ-
entiated adult cells, and Myc is reactivated in the tumors aris-
ing in the chimeric mice derived from such cells (38). Thus, it
is conceivable that Myc displays common pathways as a “stem
cell-ness” keeper and as an oncogene, preventing differentia-
tion in both cases. Our results in the K562 model support the
hypothesis that inhibition of cell differentiation is a Myc tu-
morigenic mechanism independent of Myc effects in cell pro-
liferation.
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